Cargando…
Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study
Background: Systemic Juvenile Idiopathic Arthritis (sJIA) is a unique category of juvenile arthritis in which interleukin 6 plays a major pathogenic role. This study aimed to describe the therapeutic short-term outcomes among patients with sJIA starting tocilizumab (TCZ) therapy and to identify poss...
Autores principales: | Nada, Doaa W., Moghazy, Abdelkawy, Allam, Abdallah El-Sayed, Alunno, Alessia, Ibrahim, Amira M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141590/ https://www.ncbi.nlm.nih.gov/pubmed/34041254 http://dx.doi.org/10.3389/fmed.2021.665028 |
Ejemplares similares
-
Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012) -
Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011) -
Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis
por: Herlin, Troels
Publicado: (2010) -
Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015) -
Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)